TickerFacts.

Jade Biosciences, Inc. (JBIO): Free Cash Flow

Operating cash flow minus capital expenditures for the same annual period and currency, computed by TickerFacts from the filed figures. A simple proxy, not a reported figure; a year without both inputs is left out.

-$94.89M
Year ended 2025-12-31
2021-12-31: -$27.58M2022-12-31: -$39.32M2023-12-31: -$56.92M2025-12-31: -$94.89M-$94.89M
2021-12-31 Free Cash Flow (USD) 2025-12-31
Period endedFree Cash FlowChange YoYSource filing
2025-12-31-$94.89Mn/a2026-03-06, From 2025-01-01
No annual figure between 2023-12-31 and 2025-12-31.
2023-12-31-$56.92Mn/m2025-03-27, From 2023-01-01
2022-12-31-$39.32Mn/m2024-03-25, From 2022-01-01
2021-12-31-$27.58Mn/a2023-03-29, From 2021-01-01

Free Cash Flow at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedFree Cash FlowChange YoY
Jade Biosciences, Inc. (JBIO)2025-12-31-$94.89Mn/a
Zymeworks Inc. (ZYME)2025-12-31-$34.53Mn/m
Upstream Bio, Inc. (UPB)2025-12-31-$133.44Mn/m
Capricor Therapeutics, Inc. (CAPR)2025-12-31-$72.72Mn/m
Lyell Immunopharma, Inc. (LYEL)2025-12-31-$150.80Mn/m
Keros Therapeutics, Inc. (KROS)2025-12-31$105.95Mn/m
Anaptysbio, Inc (ANAB)2025-12-31$19.61Mn/m
Fulcrum Therapeutics, Inc. (FULC)2025-12-31-$60.38Mn/m
Amylyx Pharmaceuticals, Inc. (AMLX)2025-12-31-$123.48Mn/m

Compare JBIO, ZYME, UPB, CAPR side by side · Screen every company in Pharmaceutical Preparations ↗